Jun Suzuki1, Evelyn Bayna, Erminia Dalle Molle, Wilbur Y W Lew. 1. Cardiology Section, Department of Medicine, V.A. San Diego Healthcare System and University of California, 3350 La Jolla Village Drive, San Diego, CA 92161, USA.
Abstract
OBJECTIVES: Apoptosis develops in several heart diseases, but the therapeutic options are limited. It was hypothesized that nicotine, which inhibits apoptosis in several cells, inhibits cardiac apoptosis induced by lipopolysaccharide (LPS). BACKGROUND: Over-the-counter nicotine produces sustained levels (10 to 25 ng/ml) that may be antiapoptotic. Low levels of LPS induce apoptosis by activating tissue renin-angiotensin to stimulate angiotensin II, type 1 (AT(1)) receptors in cardiac myocytes. METHODS: Adult Sprague Dawley rats were pretreated with nicotine (6 mg/kg/day) or saline for seven to ten days (miniosmotic pumps). The LPS (1 mg/kg) was injected intravenously. Toll-like receptor 4 (TLR4) and angiotensinogen messenger ribonucleic acid (mRNA) were measured in the heart after 0, 4, 8, 16, and 24 h. Cardiac apoptosis was measured by terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining after 24 h. In vitro effects of LPS (10 ng/ml, 24 h) were studied in cardiac myocytes isolated from rats pretreated with nicotine for 7 to 10 days, or after pre-exposing myocytes to nicotine (15 ng/ml) for 1, 4, 16, or 24 h. RESULTS: Neither nicotine nor LPS affected systolic blood pressure. The LPS increased cardiac apoptosis after 24 h in saline-treated, but not nicotine-treated rats, despite similar increases in cardiac TLR4 and angiotensinogen mRNA over 8 to 16 h. The LPS-induced apoptosis was blocked by pre-exposing myocytes to nicotine for 4 to 24 h (partial inhibition after 1 h). Nicotine did not inhibit apoptosis induced by angiotensin II (100 nM, 24 h). CONCLUSIONS: Therapeutic levels of nicotine inhibit LPS-induced cardiac apoptosis. This occurs after LPS increases TLR4 and angiotensinogen mRNA, but proximal to AT(1) receptor activation. Nicotine may be a novel inhibitor of cardiac apoptosis in conditions associated with circulating LPS (e.g., decompensated heart failure, acute and chronic infections).
OBJECTIVES: Apoptosis develops in several heart diseases, but the therapeutic options are limited. It was hypothesized that nicotine, which inhibits apoptosis in several cells, inhibits cardiac apoptosis induced by lipopolysaccharide (LPS). BACKGROUND: Over-the-counter nicotine produces sustained levels (10 to 25 ng/ml) that may be antiapoptotic. Low levels of LPS induce apoptosis by activating tissue renin-angiotensin to stimulate angiotensin II, type 1 (AT(1)) receptors in cardiac myocytes. METHODS: Adult Sprague Dawley rats were pretreated with nicotine (6 mg/kg/day) or saline for seven to ten days (miniosmotic pumps). The LPS (1 mg/kg) was injected intravenously. Toll-like receptor 4 (TLR4) and angiotensinogen messenger ribonucleic acid (mRNA) were measured in the heart after 0, 4, 8, 16, and 24 h. Cardiac apoptosis was measured by terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining after 24 h. In vitro effects of LPS (10 ng/ml, 24 h) were studied in cardiac myocytes isolated from rats pretreated with nicotine for 7 to 10 days, or after pre-exposing myocytes to nicotine (15 ng/ml) for 1, 4, 16, or 24 h. RESULTS: Neither nicotine nor LPS affected systolic blood pressure. The LPS increased cardiac apoptosis after 24 h in saline-treated, but not nicotine-treated rats, despite similar increases in cardiac TLR4 and angiotensinogen mRNA over 8 to 16 h. The LPS-induced apoptosis was blocked by pre-exposing myocytes to nicotine for 4 to 24 h (partial inhibition after 1 h). Nicotine did not inhibit apoptosis induced by angiotensin II (100 nM, 24 h). CONCLUSIONS: Therapeutic levels of nicotine inhibit LPS-induced cardiac apoptosis. This occurs after LPS increases TLR4 and angiotensinogen mRNA, but proximal to AT(1) receptor activation. Nicotine may be a novel inhibitor of cardiac apoptosis in conditions associated with circulating LPS (e.g., decompensated heart failure, acute and chronic infections).
Authors: Alexandre Kanashiro; Fabiane Sônego; Raphael G Ferreira; Fernanda V S Castanheira; Caio A Leite; Vanessa F Borges; Daniele C Nascimento; David F Cólon; José Carlos Alves-Filho; Luis Ulloa; Fernando Q Cunha Journal: Pharmacol Res Date: 2016-12-12 Impact factor: 7.658
Authors: Juan Arredondo; Alexander I Chernyavsky; Lisa M Marubio; Arthur L Beaudet; David L Jolkovsky; Kent E Pinkerton; Sergei A Grando Journal: Am J Pathol Date: 2005-02 Impact factor: 4.307
Authors: Jin Yu; Ngan F Huang; Kitchener D Wilson; Jeffrey B Velotta; Mei Huang; Zongjin Li; Andrew Lee; Robert C Robbins; John P Cooke; Joseph C Wu Journal: PLoS One Date: 2009-09-15 Impact factor: 3.240
Authors: Wilbur Y W Lew; Evelyn Bayna; Erminia Dalle Molle; Nancy D Dalton; N Chin Lai; Valmik Bhargava; Vincent Mendiola; Paul Clopton; Tong Tang Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240
Authors: Konstantinos E Farsalinos; Giorgio Romagna; Elena Allifranchini; Emiliano Ripamonti; Elena Bocchietto; Stefano Todeschi; Dimitris Tsiapras; Stamatis Kyrzopoulos; Vassilis Voudris Journal: Int J Environ Res Public Health Date: 2013-10-16 Impact factor: 3.390